

**S3 Table.** Correlation between CEA-response and the extent of tumor shrinkage according to target agents (cetuximab and bevacizumab)

	Tumor shrinkage in assessable patients							
	In RECIST-PR patients				In RECIST-SD patients			
	Median (%)	≤ 50%	> 50%	P-value	Median (%)	≤ 0%	> 0%	P-value
<b>In patients with chemotherapy with cetuximab</b>								
CEA-CR	58	0	4 (100)	0.043	13	1 (50.0)	1 (50.0)	0.285
CEA-PR	70	3 (33.3)	6 (66.7)		-1	3 (75.0)	1 (25.0)	
CEA-SD	53	3 (50.0)	3 (50.0)		NA	0	1 (100)	
CEA-PD	NA	1 (100)	0		NA	0	1 (100)	
<b>In patients with chemotherapy with bevacizumab</b>								
CEA-CR	48	4 (57.1)	3 (42.9)	0.874	28	1 (50.0)	1 (50.0)	0.592
CEA-PR	56	7 (41.2)	10 (58.8)		10	2 (50.0)	2 (50.0)	
CEA-SD	30	1 (50.0)	1 (50.0)		-3	2 (50.0)	2 (50.0)	
CEA-PD	34	2 (50.0)	2 (50.0)		NA	0	1 (100)	

Values are presented as number (%) unless otherwise indicated. CEA, carcinoembryonic antigen; RECIST, response evaluation criteria in solid tumor; PR, partial response; SD, stable disease; CR, complete response; NA, not available; PD, progressive disease.